Your browser is no longer supported. Please, upgrade your browser.
Cabaletta Bio, Inc.
Index- P/E- EPS (ttm)-1.48 Insider Own3.20% Shs Outstand23.76M Perf Week-3.34%
Market Cap221.45M Forward P/E- EPS next Y-2.42 Insider Trans-47.21% Shs Float22.80M Perf Month-13.95%
Income-35.60M PEG- EPS next Q-0.49 Inst Own64.00% Short Float7.50% Perf Quarter-24.18%
Sales- P/S- EPS this Y-55.50% Inst Trans-2.49% Short Ratio15.09 Perf Half Y-33.69%
Book/sh4.35 P/B2.13 EPS next Y-16.30% ROA-30.20% Target Price- Perf Year32.90%
Cash/sh4.26 P/C2.17 EPS next 5Y- ROE-31.30% 52W Range6.35 - 16.38 Perf YTD-25.88%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.53% Beta-
Dividend %- Quick Ratio26.60 Sales past 5Y- Gross Margin- 52W Low45.72% ATR0.80
Employees34 Current Ratio26.60 Sales Q/Q- Oper. Margin- RSI (14)39.73 Volatility8.63% 8.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-23.70% Profit Margin- Rel Volume0.61 Prev Close8.78
ShortableYes LT Debt/Eq0.00 EarningsMar 16 BMO Payout- Avg Volume113.36K Price9.25
Recom2.00 SMA20-10.80% SMA50-15.13% SMA200-22.89% Volume69,005 Change5.35%
Jan-08-21Initiated Chardan Capital Markets Buy $21
Oct-13-20Initiated H.C. Wainwright Buy $20
Nov-19-19Initiated Morgan Stanley Overweight $19
Nov-19-19Initiated Evercore ISI Outperform $25
Nov-19-19Initiated Cowen Outperform
May-03-21 01:17PM  
Apr-27-21 11:10AM  
Apr-20-21 02:33AM  
Apr-07-21 08:00AM  
Mar-16-21 07:30AM  
Jan-19-21 11:37PM  
Jan-07-21 08:00AM  
Jan-04-21 08:00AM  
Dec-08-20 04:30PM  
Dec-04-20 08:25AM  
Nov-23-20 08:00AM  
Nov-10-20 07:30AM  
Oct-31-20 08:00AM  
Oct-22-20 07:39AM  
Sep-25-20 08:00AM  
Sep-08-20 08:00AM  
Aug-25-20 08:00AM  
Aug-06-20 07:30AM  
Aug-03-20 08:00AM  
Jul-24-20 07:42AM  
Jul-07-20 08:00AM  
Jun-24-20 04:25PM  
Jun-01-20 12:00PM  
May-28-20 08:00AM  
May-27-20 08:00AM  
May-18-20 04:30PM  
May-12-20 07:00AM  
May-06-20 08:00AM  
Apr-17-20 12:00PM  
Mar-30-20 07:00AM  
Feb-20-20 08:00AM  
Jan-30-20 09:26AM  
Jan-29-20 08:00AM  
Dec-23-19 04:32AM  
Nov-26-19 08:00AM  
Oct-25-19 05:10PM  
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
5AM Ventures V, L.P.10% OwnerJan 12Sale13.0085,0001,105,000369,688Jan 12 05:07 PM
5AM Ventures V, L.P.10% OwnerJan 08Sale13.00302,0003,926,000380,218Jan 12 05:07 PM
5AM Ventures V, L.P.10% OwnerDec 10Sale14.75298,0004,395,500417,629Dec 14 05:58 PM